Endo Pharma (ENDP) Tops Q3 EPS by 23c; Boosts FY13 Outlook

November 5, 2013 6:35 AM EST Send to a Friend
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q3 EPS of $1.34, $0.23 better than the analyst estimate of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login